Format

Send to

Choose Destination
Surg Clin North Am. 2018 Aug;98(4):687-702. doi: 10.1016/j.suc.2018.03.005. Epub 2018 May 21.

Incorporating Biologic Factors into the American Joint Committee on Cancer Breast Cancer Staging System: Review of the Supporting Evidence.

Author information

1
Breast Surgical Oncology, Dana-Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, Suite 1470, Boston, MA 02215, USA.
2
Breast Surgical Oncology, Dana-Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, Suite 1220, Boston, MA 02215, USA.
3
Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1434, Houston, TX 77030, USA.
4
Breast Surgical Oncology, Dana-Farber/Brigham and Women's Cancer Center, 450 Brookline Avenue, Suite 1470, Boston, MA 02215, USA. Electronic address: emittendorf@bwh.harvard.edu.

Abstract

The American Joint Committee on Cancer staging system has evolved in response to improved imaging, refined surgical techniques, enhanced pathologic evaluation, and greater understanding of tumor biology. The 8th edition has introduced clinical and pathologic prognostic stages for breast cancer that incorporate biologic variables (grade, estrogen/progesterone receptor status, HER2 status, multigene panels) with TNM categories that define the anatomic stage. The prognostic staging system facilitates more refined stratification than the anatomic stage with respect to survival and is an important advance that maintains the clinical relevance of the staging system by taking into account tumor biology and current treatment algorithms.

KEYWORDS:

AJCC staging System; Anatomic stage; Biomarkers; Breast cancer; Prognostic stage

PMID:
30005768
DOI:
10.1016/j.suc.2018.03.005
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center